Clinical Study of 8 Cases of CHD2 Gene Mutation–Related Neurological Diseases and Their Mechanisms

Xiaona Luo, Xiaoang Sun, Yilin Wang, Longlong Lin, Fang Yuan, Simei Wang, Wenjing Zhang, Xiaobing Ji, Meiyan Liu, Shengnan Wu, Xiaoping Lan, Jie Zhang, Jingbin Yan, Fanyi Zeng, Yucai ChenFrontiers in Cell and Developmental Biology 2022 · DOI

This clinical study explores the genetic landscape and molecular mechanisms of CHD2 gene mutations, identifying four previously unknown mutations and linking them to an upregulation of the REST gene, which may explain the resulting neurological symptoms.

TL;DR

Researchers identified four novel mutations in the CHD2 gene among a cohort of eight pediatric patients with epilepsy and intellectual disability. Surprisingly, while CHD2 expression levels remained normal, the mutations triggered a significant increase in the expression of REST—a master repressor of neuronal genes—suggesting a regulatory "misfire" rather than a simple loss of protein.

What Problem Does This Paper Address?

The CHD2 (chromodomain helicase DNA-binding protein 2) gene acts as a "chromatin architect." It encodes an enzyme that reshapes how DNA is packaged, essentially deciding which genes are accessible for the cell to read. Mutations in CHD2 are known to cause a spectrum of neurological issues, including "Dravet-like" epilepsy, intellectual disability (ID), and autism.

However, the "how" remains a mystery. While we know these mutations are autosomal dominant (meaning only one faulty copy of the gene is needed to cause disease), it wasn't clear if the disease stems from having too little CHD2 protein (haploinsufficiency) or if the mutant protein actively interferes with cellular processes. This paper seeks to bridge the gap between clinical symptoms and molecular mechanisms.

Methods

The researchers conducted a multi-modal study involving eight pediatric patients at Shanghai Children’s Hospital:

  • Genetic Sequencing: They used Whole-Exome Sequencing (WES) and targeted gene panels to pinpoint specific mutations.
  • Expression Analysis: Using quantitative PCR (qPCR), they measured the mRNA levels of both CHD2 and REST (Repressor Element 1-Silencing Transcription Factor) in the patients' blood.
  • Conservation Analysis: They compared the mutated protein sequences across various species (from humans to zebrafish) to determine if the mutations occurred in "high-stakes" areas of the protein that haven't changed over millions of years of evolution.
  • Clinical Correlation: They tracked seizure types, MRI results, and medication efficacy (specifically looking at Valproate).

Datasets

  • Patient Cohort: A primary dataset of 8 pediatric patients and their parents (trios) from Shanghai Children’s Hospital.
  • Reference Databases: The study utilized the Human Gene Mutation Database (HGMD 2020.6), which at the time contained 128 reported cases of CHD2 mutations, to compare their findings against known variants.

Key Insights and Ideas

  • The Expression Paradox: In many genetic diseases, a mutation leads to a drop in the gene's expression. Here, the researchers found that CHD2 mRNA levels in patients were nearly identical to healthy controls. This suggests that the clinical symptoms aren't caused by a lack of CHD2 production, but likely by the presence of a dysfunctional "mutant" protein that still hangs around in the cell.
  • The REST Connection: The most striking finding was the significant increase in REST gene expression. REST is a protein that normally silences neuronal genes in non-neuronal cells. If REST is overactive in the brain, it could prematurely "shut down" genes essential for healthy brain development and synaptic plasticity.
  • Conservation is Key: All identified mutations occurred at highly conserved amino acid positions. This reinforces the idea that these specific spots in the CHD2 protein are vital for its function; even a tiny change there is enough to disrupt the complex machinery of chromatin remodeling.
  • Phenotypic Variability: The study noted that even patients with the exact same mutation showed different clinical severities. This implies that CHD2 doesn't act alone—other "modifier genes" or environmental factors likely influence how the disease manifests.

Key Results

  • Discovery of New Variants: The team identified six distinct mutations. Four were entirely new to science: c.670C>T, c.4012A>C, c.2416dup, and c.1727–1728insAT.
  • High Seizure Incidence: 87.5% of the cohort experienced epilepsy, with an average onset age ranging from 40 days to 5 years.
  • Treatment Success: Among various anti-epileptic drugs, Valproate (VPA) showed the best clinical results for controlling seizures in these patients.
  • Molecular Signature: qPCR confirmed that REST expression was significantly higher in patients compared to controls ($p < 0.05$), providing a potential molecular "smoking gun" for the disease mechanism.

Limitations and Future Work

The authors acknowledge a few hurdles:

  1. Sample Size: With only eight patients, the statistical power is limited, especially regarding the diversity of clinical phenotypes.
  2. Tissue Specificity: The expression data was derived from blood samples. While useful, mRNA levels in the blood may not perfectly mirror the complex regulatory environment of the human brain.
  3. Mechanism Gap: While the link between CHD2 mutation and REST upregulation is clear, the exact biochemical pathway—how CHD2 normally keeps REST in check—remains speculative and requires further functional studies in cell or animal models.

Future research will likely focus on whether targeting the REST pathway could serve as a potential therapeutic strategy for children with CHD2-related neurodevelopmental disorders.

Summary updated

Abstract

<b>Background:</b> The chromodomain helicase DNA-binding protein 2 (<i>CHD2</i>) gene, is an ATPase and part of the <i>CHD</i> family of chromatin remodelers. Mutations in the <i>CHD2</i> gene are inherited in an autosomal-dominant manner and can lead to intellectual disability, epilepsy, and autism. We investigated the clinical characteristics of <i>CHD2</i>-related conditions and their possible pathogenesis. <b>Methods:</b> We collected and analysed the clinical data of patients that were identified as having <i>CHD2</i> mutations. Genetic testing was performed using targeted sequencing or whole-exome sequencing. We analysed the expression of <i>CHD2</i> and repressor element 1-silencing transcription factor (<i>REST</i>) in blood samples using quantitative PCR and the conservation of the mutations. The <i>CHD2</i> mutations we identified were compared with the known mutations reported in the <i>CHD2</i>-related literature. <b>Results:</b> Eight patients with <i>CHD2</i> gene mutations were analysed. Six mutations were identified; four were unreported previously (c.670C>T; c.4012A>C; c.2416dup; c.1727-1728insAT), and two were known mutations: c.5035C>T (two cases) and c.4173dup (two cases). Among these mutations, seven were <i>de novo</i> mutations, and one could not be determined because the parents refused genetic testing. The clinical manifestations included mild or severe intellectual disability, epilepsy, and behavioural abnormalities. Quantitative PCR showed that the <i>CHD2</i> gene expression levels among the patients, parents, and the controls were not significantly different. The levels of <i>REST</i> gene expression in the patients were significantly higher than those of the controls; thus, mutation of the <i>CHD2</i> gene led to an increase in the expression level of the <i>REST</i> gene. The mutations reported were all located in conserved positions in different species. Among the various medications administered for treatment, valproate showed the best results for the treatment of epilepsy caused by <i>CHD2</i> gene mutation. <b>Conclusion:</b> Mutation in <i>CHD2</i> did not lead to a significant decrease in its expression level, indicating that the clinical phenotype was unrelated to its expression level, and the mutant protein may retain some function. Most of the mutations relatively stable. In addition, the clinical manifestations from the same mutation in the <i>CHD2</i> gene were different among the known cases; this may be related to the regulation of <i>REST</i> or other regulatory factors.
BibTeX
@inproceedings{luo2022clinical,
  author = {Xiaona Luo and Xiaoang Sun and Yilin Wang and Longlong Lin and Fang Yuan and Simei Wang and Wenjing Zhang and Xiaobing Ji and Meiyan Liu and Shengnan Wu and Xiaoping Lan and Jie Zhang and Jingbin Yan and Fanyi Zeng and Yucai Chen},
  title = {{Clinical Study of 8 Cases of CHD2 Gene Mutation–Related Neurological Diseases and Their Mechanisms}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2022},
  doi = {10.3389/fcell.2022.853127},
}
Figure